Represents duration of agreement for collaborative agreement.

No definition available.

Name:	dyai_CollaborativeArrangementDurationOfAgreement
Namespace Prefix:	dyai_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents equity interest acquired for collaborative agreement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementEquityInterestAcquired
Namespace Prefix:	dyai_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents maximum obligation for research and development for collaborative agreement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents minimum obligation for research and development for collaborative agreement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of antibodies and vaccines for development and commercialization for collaborate arrangement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementNumberOfAntibodiesAndVaccinesForDevelopmentAndCommercialization
Namespace Prefix:	dyai_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents number of shares to be received for collaborative arrangement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementNumberOfSharesToBeReceived
Namespace Prefix:	dyai_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents number of proteins for option to obtain exclusive commercial sub-lease of collaborative agreement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementOptionToObtainExclusiveCommercialSublicenseForNumberOfProteins
Namespace Prefix:	dyai_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents outstanding commitment for collaborative.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementOutstandingCommitment
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents payments for additional development and commercialization for collaborative arrangement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents payment for research and development agreement for collaborate arrangement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents period of milestone payments and royalties for research funding of collaborative arrangement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod
Namespace Prefix:	dyai_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents percentage of revenue sharing for collaborate arrangement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementRevenueSharingPercentage
Namespace Prefix:	dyai_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents vesting percentage for collaborative arrangement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementVestingPercentages
Namespace Prefix:	dyai_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents ownership percentage by noncontrolling owners for noncontrolling interest.

+ References

No definition available.

+ Details

Name:	dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	dyai_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of ownership.

+ References

No definition available.

+ Details

Name:	dyai_OwnershipPercentage
Namespace Prefix:	dyai_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the amount of related-party research and development expense recognized during the period.

+ References

No definition available.

+ Details

Name:	dyai_ResearchAndDevelopmentExpenseRelatedParty
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents revenue from collaborative arrangement recognized during period.

+ References

No definition available.

+ Details

Name:	dyai_RevenueFromCollaborativeArrangementRecognized
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of investment in equity security without readily determinable fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714

+ Details

Name:	us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dyai_SerumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedContractCostAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedContractCostAxis=dyai_ServiceFrameworkAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=dyai_AlphazymeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=dyai_IDBiologicsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=dyai_BDIHoldingsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=dyai_VLPbioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Note 3 - Research and Collaboration Agreements, Sublicense Agreement and Investments in Privately Held Companies (Details Textual) € in Millions					12 Months Ended
	Jun. 24, 2020	May 07, 2019	Jun. 30, 2017 USD ($)	Jun. 30, 2017 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 01, 2020	Jul. 08, 2020 shares	Apr. 26, 2019	Jun. 30, 2017 EUR (€)
Collaborative Arrangement, Duration Of Agreement (Year)			2 years	2 years
Collaborative Arrangement, Payment for Research and Development Agreement			$ 1,100,000	€ 1.0
Research and Development Expense, Related Party					$ 0	$ 868,720
Collaborative Arrangement [Member] \| Serum [Member]
Collaborative Arrangement, Number of Antibodies and Vaccines For Development and Commercialization		12
Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins		12
Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period (Year)		15 years
Revenue from Collaborative Arrangement, Recognized					244,000	$ 118,000
Novovet [Member]
Equity Method Investment, Ownership Percentage									20.00%
Alphazyme [Member]
Sale of Stock, Percentage of Ownership after Transaction	2.50%
Equity Securities without Readily Determinable Fair Value, Amount					$ 284,709
Research Services Agreement [Member]
Collaborative Arrangement, Payment for Additional Development and Commercialization \| €										€ 1.5
Service Framework Agreement [Member]
Collaborative Arrangement, Duration Of Agreement (Year)			2 years	2 years
Collaborative Arrangement, Minimum Obligation For Research and Development			$ 1,000,000
Collaborative Arrangement, Outstanding Commitment			$ 1,000,000
Alphazyme [Member]
Ownership Percentage							1.99%
ID Biologics Inc [Member]
Collaborative Arrangement, Number of Shares To Be Received (in shares) \| shares								129,611
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners								0.37%
ID Biologics Inc [Member] \| Share-based Payment Arrangement, Tranche One [Member]
Collaborative Arrangement, Vesting Percentages								50.00%
ID Biologics Inc [Member] \| Share-based Payment Arrangement, Tranche Two [Member]
Collaborative Arrangement, Vesting Percentages								25.00%
ID Biologics Inc [Member] \| Share-based Payment Arrangement, Tranche Three [Member]
Collaborative Arrangement, Vesting Percentages								25.00%
Research Services Agreement [Member]
Collaborative Arrangement, Payment for Research and Development Agreement \| €				€ 1.0
Research Services Agreement [Member] \| BDI Holdings [Member]
Collaborative Arrangement, Duration Of Agreement (Year)			2 years	2 years
Collaborative Arrangement, Equity Interest Acquired			16.10%	16.10%
Collaborative Arrangement, Minimum Obligation For Research and Development			$ 936,000
Collaborative Arrangement, Maximum Obligation For Research and Development \| €										8.0
Research Services Agreement [Member] \| BDI Holdings [Member] \| Minimum [Member]
Collaborative Arrangement, Minimum Obligation For Research and Development \| €										€ 1.0
Collaborative Arrangement, Revenue Sharing, Percentage			50.00%	50.00%
Research Services Agreement [Member] \| BDI Holdings [Member] \| Maximum [Member]
Collaborative Arrangement, Revenue Sharing, Percentage			75.00%	75.00%
Research Services Agreement [Member] \| VL Pbio Member
Collaborative Arrangement, Equity Interest Acquired			3.30%	3.30%